Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: A long-term single center experience

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 2, 2012, Pages 136-140

  Kim, Kyubo ^a   Chie, Eui Kyu ^a   Jang, Jin Young ^a   Kim, Sun Whe ^a   Han, Sae Won ^a   Oh, Do Youn ^a   Im, Seock Ah ^a   Kim, Tae You ^a   Bang, Yung Jue ^a   Ha, Sung W ^a  

^a Seoul National University   (South Korea)

Author keywords

Adjuvant chemoradiotherapy; Extrahepatic bile duct cancer; Prognostic factor

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; UFT; ANTINEOPLASTIC AGENT; MITOMYCIN;

ABDOMINAL PAIN; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; DIARRHEA; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; EXTRAHEPATIC BILE DUCT ADENOCARCINOMA; EXTRAHEPATIC BILE DUCT CANCER; FEMALE; FOLLOW UP; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; POSTOPERATIVE CARE; RADIATION DOSE; TREATMENT OUTCOME; VOMITING; ADENOCARCINOMA; ANALYSIS OF VARIANCE; BILE DUCT TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEPATIC DUCT; KAPLAN MEIER METHOD; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TIME; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860633130     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318209aa29     Document Type: Article

References (26)

1. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet. 2005;366:1303-1314. (Pubitemid 41416587)
2. Anderson CD, Pinson W, Berlin J, et al. Diagnosis and treatment of cholangiocarcinoma. Oncologist. 2004;9:43-57. (Pubitemid 38134013)
3. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma. Cancer. 2003;98:1689-1700. (Pubitemid 37238626)
4. González González D, Gerard JP, Maners AW, et al. Results of radiation therapy in carcinoma of the proximal bile duct (Klatskin tumor). Semin Liver Dis. 1990;10:131-141. (Pubitemid 20214609)
5. Cameron JL, Pitt HA, Zinner MJ, et al. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg. 1990;159:91-98. (Pubitemid 20045317)
6. Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys. 2000;46: 581-587. (Pubitemid 30100635)
7. Gerhards MF, van Gulik TM, Gonzalez DG, et al. Results of postoperative radiotherapy for respectable hilar cholangiocarcinoma. World J Surg. 2003;27:173-179. (Pubitemid 36920167)
8. Kim S, Kim SW, Bang YJ, et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys. 2002;54:414-419. (Pubitemid 35286806)
9. Stein DE, Heron DE, Rosato EL, et al. Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am J Clin Oncol. 2005;28:21-23. (Pubitemid 40209319)
10. Oh D, Lim DH, Heo JS, et al. The role of adjuvant radiotherapy in microscopic tumor control after extrahepatic bile duct cancer surgery. Am J Clin Oncol. 2007;30:21-25. (Pubitemid 46213820)
11. American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Handbook. 6th ed. New York: Springer-Verlag; 2002.
12. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
13. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214. (Pubitemid 11167383)
14. Lillemoe KD, Cameron JL. Surgery for hilar cholangiocarcinoma: The Johns Hopkins approach. J Hepatobiliary Pancreat Surg. 2000;7:115-121.
15. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, respectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507-517.
16. Nakeeb A, Tran KQ, Black MJ, et al. Improved survival in resected biliary malignancies. Surgery. 2002;132:555-563.
17. D'Angelica M, Jarnagin WR, Blumgart LH. Resectable hilar cholangiocarcinoma: Surgical treatment and long-term outcome. Surg Today. 2004;34:885-890. (Pubitemid 40326463)
18. Borghero Y, Crane CH, Szklaruk J, et al. Extrahepatic bile duct adenocarcinoma: Patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008;15:3147-3156.
19. Gwak HK, Kim WC, Kim HJ, et al. Extrahepatic bile duct cancers: Surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2010;78:194-198.
20. Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009;73:148-153.
21. Shivnani AT, Lee CM, Tward JD, et al. Survival outcomes for adjuvant radiation therapy versus no radiation therapy in extrahepatic cholangiocarcinoma: A Surveillance, Epidemiology, and End Results (SEER) analysis. Int J Radiat Oncol Biol Phys. 2008;72(suppl.):S283.
22. Dubben HH, Krüll A, Beck-Bornholdt HP. Split-course radiotherapy: Where do we stand? Strahlenther Onkol. 2001;177: 227-239. (Pubitemid 32428328)
23. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007;68:654-661. (Pubitemid 46818766)
24. Klempnauer J, Ridder GJ, von Wasielewski R, et al. Resectional surgery of hilar cholangiocarcinoma: A multivariate analysis of prognostic factors. J Clin Oncol. 1997;15:947-954. (Pubitemid 27106276)
25. Murakami Y, Uemura K, Hayashidani Y, et al. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J Surg Oncol. 2007;95:207-212.
26. Lim KH, Oh DY, Chie EK, et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: A non-randomized, single center study. BMC Cancer. 2009;9:345.